Allergy allergy NN
immunotherapy immunotherapy NN
-LRB- -lrb- -LRB-
AIT ait NN
-RRB- -rrb- -RRB-
is be VBZ
a a DT
treatment treatment NN
option option NN
for for IN
respiratory respiratory JJ
allergy allergy NN
that that WDT
is be VBZ
complementary complementary JJ
to to TO
pharmacotherapy pharmacotherapy NN
with with IN
a a DT
distinct distinct JJ
mechanism mechanism NN
of of IN
action action NN
Alternative alternative JJ
methods method NNS
to to TO
subcutaneous subcutaneous JJ
administration administration NN
of of IN
AIT AIT NNP
that that WDT
enable enable VBP
patients patient NNS
to to TO
safely safely RB
self-administer self-administer VB
AIT AIT NNP
is be VBZ
considered consider VBN
an a DT
unmet unmet JJ
clinical clinical JJ
need need NN
The the DT
sublingual sublingual JJ
immunotherapy immunotherapy NN
tablet tablet NN
-LRB- -lrb- -LRB-
SLIT-tablet slit-tablet NN
-RRB- -rrb- -RRB-
is be VBZ
an a DT
orally orally RB
disintegrating disintegrate VBG
pharmaceutical pharmaceutical JJ
formulation formulation NN
-LRB- -lrb- -LRB-
oral oral JJ
lyophilisate lyophilisate NN
-RRB- -rrb- -RRB-
containing contain VBG
standardized standardized JJ
allergens allergen NNS
SLIT-tablets slit-tablet NNS
have have VBP
been be VBN
developed develop VBN
for for IN
sublingual sublingual JJ
immunotherapy immunotherapy NN
-LRB- -lrb- -LRB-
SLIT slit NN
-RRB- -rrb- -RRB-
of of IN
cedar-pollen cedar-pollen NN
grass-pollen grass-pollen NN
ragweed-pollen ragweed-pollen NN
tree-pollen tree-pollen NN
and and CC
house house NN
dust dust NN
mite mite JJ
allergies allergy NNS
It it PRP
is be VBZ
a a DT
once-daily once-daily JJ
tablet tablet NN
treatment treatment NN
to to TO
be be VB
self-administered self-administered JJ
after after IN
the the DT
first first JJ
dose dose NN
has have VBZ
been be VBN
provided provide VBN
under under IN
the the DT
supervision supervision NN
of of IN
a a DT
physician physician NN
with with IN
experience experience NN
in in IN
the the DT
diagnosis diagnosis NN
and and CC
treatment treatment NN
of of IN
allergic allergic JJ
diseases disease NNS
Once once RB
the the DT
first first JJ
dose dose NN
is be VBZ
adequately adequately RB
tolerated tolerate VBN
subsequent subsequent JJ
doses dose NNS
may may MD
be be VB
self-administered self-administered JJ
SLIT-tablets slit-tablet NNS
have have VBP
proven prove VBN
efficacy efficacy NN
for for IN
allergic allergic JJ
rhinitis rhinitis NN
-LRB- -lrb- -LRB-
AR ar NN
-RRB- -rrb- -RRB-
with with IN
and and CC
without without IN
conjunctivitis conjunctivitis NN
-LRB- -lrb- -LRB-
C c NN
-RRB- -rrb- -RRB-
and and CC
allergic allergic JJ
asthma asthma NN
-LRB- -lrb- -LRB-
AA aa NN
-RRB- -rrb- -RRB-
in in IN
adults adult NNS
children child NNS
and and CC
poly-sensitized poly-sensitized JJ
allergic allergic JJ
patients patient NNS
Meta-analyses meta-analysis NNS
indicate indicate VBP
that that IN
SLIT-tablets slit-tablet NNS
have have VBP
superior superior JJ
or or CC
similar similar JJ
efficacy efficacy NN
compared compare VBN
with with IN
anti-allergic anti-allergic JJ
pharmacotherapies pharmacotherapy NNS
for for IN
seasonal seasonal JJ
AR ar NNS
and and CC
superior superior JJ
efficacy efficacy NN
for for IN
perennial perennial JJ
AR ar NNS
SLIT-tablets slit-tablet NNS
have have VBP
also also RB
demonstrated demonstrate VBN
clinically clinically RB
relevant relevant JJ
improvements improvement NNS
of of IN
asthma asthma NN
with with IN
significant significant JJ
reductions reduction NNS
in in IN
the the DT
following following NN
daily daily JJ
inhaled inhale VBN
corticosteroid corticosteroid NN
use use NN
risk risk NN
of of IN
asthma asthma NN
exacerbations exacerbation NNS
and and CC
asthma asthma NN
symptoms symptom NNS
SLIT-tablets slit-tablet NNS
are be VBP
generally generally RB
well well RB
tolerated tolerate VBD
with with IN
a a DT
low low JJ
risk risk NN
of of IN
systemic systemic JJ
allergic allergic JJ
reactions reaction NNS
The the DT
most most RBS
common common JJ
treatment-related treatment-related JJ
adverse adverse JJ
events event NNS
are be VBP
mild-moderate mild-moderate JJ
oral oral JJ
reactions reaction NNS
Current current JJ
evidence evidence NN
supports support VBZ
SLIT-tablets slit-tablet NNS
to to TO
be be VB
considered consider VBN
as as IN
an a DT
alternative alternative JJ
or or CC
add-on add-on JJ
treatment treatment NN
to to TO
pharmacotherapy pharmacotherapy NN
for for IN
AR/C ar/c NN
and and CC
asthma asthma NN
Future future JJ
SLIT SLIT NNP
developments development NNS
may may MD
include include VB
early early JJ
intervention intervention NN
to to TO
prevent prevent VB
the the DT
development development NN
or or CC
progression progression NN
of of IN
allergic allergic JJ
disease disease NN
in in IN
children child NNS
